prader willi glp 1 Prader–Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach | Current Obesity Reports GLP-1 Pipeline Update: February 2025

In the US, for instance, the number of people without diabetes but with overweight or obesity who had used a GLP-1 agonist rose from around 21,000 in 2019 to over 174,000 in 2023 a rise of more than 700% in four years [BMJ July 2024]

5, May 2001, pp

Patients who switched from tirzepatide to orforglipron maintained a mean 74.7% of their body weight reduction from the SURMOUNT-5 trial compared with those in the placebo group, which maintained a mean 49.2% of their weight loss

10.1038/nnano.2011.220 80 HoetP

Because of its metabolism-supporting characteristics, patients can achieve healthy lean muscle mass , heal faster from injuries, and maintain healthy bones and ligaments